Skip to main content
Top
Published in: Abdominal Radiology 11/2018

01-11-2018 | Pictorial essay

Cinematic rendering of pancreatic neoplasms: preliminary observations and opportunities

Authors: Linda C. Chu, Pamela T. Johnson, Elliot K. Fishman

Published in: Abdominal Radiology | Issue 11/2018

Login to get access

Abstract

Pancreatic cancer is the third most common cause of cancer death and CT is the most commonly used modality for the initial evaluation of suspected pancreatic cancer. Post-processing of CT data into 2D multiplanar and 3D reconstructions has been shown to improve tumor visualization and assessment of tumor resectability compared to axial slices, and is considered the standard of care. Cinematic rendering is a new 3D-rendering technique that produces photorealistic images, and it has the potential to more accurately depict anatomic detail compared to traditional 3D reconstruction techniques. The purpose of this article is to describe the potential application of CR to imaging of pancreatic neoplasms. CR has the potential to improve visualization of subtle pancreatic neoplasms, differentiation of solid and cystic pancreatic neoplasms, assessment of local tumor extension and vascular invasion, and visualization of metastatic disease.
Literature
19.
go back to reference Fellner FA (2016) Introducing cinematic rendering: a novel technique for post-processing medical imaging data. J Biomed Sci Eng 9:170–175CrossRef Fellner FA (2016) Introducing cinematic rendering: a novel technique for post-processing medical imaging data. J Biomed Sci Eng 9:170–175CrossRef
29.
go back to reference Chang ST, Jeffrey RB, Patel BN, et al. (2016) Preoperative multidetector CT diagnosis of extrapancreatic perineural or duodenal invasion is associated with reduced postoperative survival after pancreaticoduodenectomy for pancreatic adenocarcinoma: preliminary experience and implications for patient care. Radiology 281(3):816–825. https://doi.org/10.1148/radiol.2016152790 CrossRefPubMed Chang ST, Jeffrey RB, Patel BN, et al. (2016) Preoperative multidetector CT diagnosis of extrapancreatic perineural or duodenal invasion is associated with reduced postoperative survival after pancreaticoduodenectomy for pancreatic adenocarcinoma: preliminary experience and implications for patient care. Radiology 281(3):816–825. https://​doi.​org/​10.​1148/​radiol.​2016152790 CrossRefPubMed
32.
go back to reference Touzios JG, Kiely JM, Pitt SC, et al. (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241(5):776–783 (discussion 783–775)CrossRefPubMedPubMedCentral Touzios JG, Kiely JM, Pitt SC, et al. (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241(5):776–783 (discussion 783–775)CrossRefPubMedPubMedCentral
Metadata
Title
Cinematic rendering of pancreatic neoplasms: preliminary observations and opportunities
Authors
Linda C. Chu
Pamela T. Johnson
Elliot K. Fishman
Publication date
01-11-2018
Publisher
Springer US
Published in
Abdominal Radiology / Issue 11/2018
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-018-1559-3

Other articles of this Issue 11/2018

Abdominal Radiology 11/2018 Go to the issue

Classics in Abdominal Radiology

The lateral crescent sign

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine